Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Assets Average (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Assets Average for 10 consecutive years, with $334.5 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 24.85% to $334.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $334.5 million through Dec 2025, down 24.85% year-over-year, with the annual reading at $365.7 million for FY2025, 1.17% down from the prior year.
  • Assets Average for Q4 2025 was $334.5 million at Cartesian Therapeutics, down from $380.8 million in the prior quarter.
  • The five-year high for Assets Average was $445.2 million in Q4 2024, with the low at $122.8 million in Q3 2023.
  • Average Assets Average over 5 years is $251.7 million, with a median of $180.9 million recorded in 2021.
  • The sharpest move saw Assets Average tumbled 32.97% in 2023, then surged 227.06% in 2024.
  • Over 5 years, Assets Average stood at $163.5 million in 2021, then rose by 5.23% to $172.1 million in 2022, then rose by 19.45% to $205.5 million in 2023, then soared by 116.58% to $445.2 million in 2024, then dropped by 24.85% to $334.5 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $334.5 million, $380.8 million, and $399.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.